To those who say Òimpossible, impractical, unrealistic,Ó we say: ÒCHALLENGE ACCEPTED.Ó We are developing new technologies and an entirely new class of innovative medicines called ÒRNAi therapeuticsÓ to treat rare genetic, cardio metabolic and acute hepatic infectious diseases. Alnylam was founded in 2002 based on a Nobel Prize winning breakthrough in biology Ð the discovery of RNA interference and a bold vision that this discovery could be used to silence disease-causing genes upstream of todayÕs medicines. We are relentless in our pursuit of new treatments. Because patients shouldnÕt have to wait for hope. Alnylam is a global and diverse company of more than 700 people with 7 programs in clinical development, including 4 late-stage programs. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we've been named a Boston Globe Top Place to Work three years in a row! We are based in Cambridge, MA with offices in Maidenhead UK, Zug Switzerland and Norton, MA.